TIRZ / IGF-1 LR3Explore study findings
What a myostatin antibody study tells us about its own target
3 numbered sourcesSource years 1992, 2026
Peptides are short chains of amino acids joined by peptide bonds. Some activate receptors involved in appetite and glucose regulation. Tirzepatide is a peptide that activates the GIP and GLP-1 receptors. IGF-1 LR3 is an engineered, extended insulin-like growth factor protein. A 2026 trial added a different molecule to tirzepatide, the antibody apitegromab. It shows how a study can measure activity at the added agent’s specific target. [1, 2, 3]
Apitegromab is designed to inhibit the activation of myostatin, a protein involved in limiting muscle growth. In the EMBRAZE trial, adults with overweight or obesity were randomized to tirzepatide with apitegromab or tirzepatide with placebo for the antibody. The investigators recorded less lean mass loss with the antibody at 24 weeks despite similar total weight changes. They also measured blood concentrations of the antibody and of latent myostatin, a marker associated with its action. The authors reported that these concentrations rose and later leveled off. [1]
This design connects an observed change in body composition with a separate measurement related to the antibody’s target. The marker provides information about apitegromab. IGF-1 LR3 is a growth-factor analog with different molecular interactions. There is no basis in EMBRAZE for assigning the antibody’s marker response to IGF-1 LR3. [1, 3]
The trial gives a defined comparison of adding apitegromab to tirzepatide. A search of PubMed and ClinicalTrials.gov identified no controlled human study of the catalog pair. Investigators would need a comparison with the exact growth factor to determine its effect and a measure that addresses its own biological activity. [1, 2, 3]
Sources
Original works cited in this article. Links open the external record in a new tab.
